PT Metro Healthcare Indonesia Tbk

As of June 30, 2026, PT Metro Healthcare Indonesia Tbk carries a market capitalization of 13.77T, placing it among publicly traded companies globally. Its enterprise value stands at 14.36T, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, PT Metro Healthcare Indonesia Tbk has 33.25B shares outstanding.

As of June 30, 2026, PT Metro Healthcare Indonesia Tbk trades at a trailing price-to-earnings ratio of 390.66. The price-to-sales ratio is 27.70, and the price-to-book ratio stands at 4.55.

As of June 30, 2026, PT Metro Healthcare Indonesia Tbk trades at an EV/EBITDA multiple of 193.77 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 28.90 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 193.77 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 14.36T versus a market cap of 13.77T, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, PT Metro Healthcare Indonesia Tbk maintains a current ratio of 0.87, meaning it holds 0.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 35.09, indicating elevated leverage, while an interest coverage ratio of 0.84 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, PT Metro Healthcare Indonesia Tbk posted a return on equity (ROE) of 1.17, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 1.72 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 0.87, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 2.91, useful for judging operating efficiency across full business cycles. The company generates approximately 575.45M in revenue per employee across its workforce of 863.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 39.10 indicates how many times PT Metro Healthcare Indonesia Tbk sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, PT Metro Healthcare Indonesia Tbk recorded 2.74B in income tax expense. That works out to an effective tax rate of 7.15, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 38.29B, leaving 35.24B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, PT Metro Healthcare Indonesia Tbk's stock has gained approximately 16.13% over the past 52 weeks. The 50-day moving average sits at 398.44, while the 200-day moving average is 454.12.

Over the twelve months ended June 30, 2026, PT Metro Healthcare Indonesia Tbk generated 496.90B in revenue and converted that into 35.24B in net income, yielding earnings per share of 1.07. EBITDA reached 74.10B, while operating income came in at 128.64B.

As of June 30, 2026, PT Metro Healthcare Indonesia Tbk holds 470.28B in cash and equivalents against 1.06T in total debt, resulting in a net debt position of 647.60B. Total book value stands at 3.02T, with working capital of -79.29B providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, PT Metro Healthcare Indonesia Tbk posted a gross margin of 55.25, reflecting its pricing power and cost economics. The operating margin of 25.89 and net profit margin of 7.09 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Total shareholder yield reaches 1.11, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to PT Metro Healthcare Indonesia Tbk shareholders.

As of June 30, 2026, PT Metro Healthcare Indonesia Tbk has an Altman Z-Score of 7.40, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.